EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024

Hidehisa Saeki, Yukihiro Ohya, Hirokazu Arakawa, Susumu Ichiyama, Toshio Katsunuma, Norito Katoh, Akio Tanaka, Hideaki Tanizaki, Yuichiro Tsunemi, Takeshi Nakahara, Mizuho Nagao, Masami Narita und 11 weitere

Allergology International · 2025-04 · 74 (2) · 210-221

DOI: 10.1016/j.alit.2025.01.003 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Allergology International, 2025-04. Verfasst von Hidehisa Saeki und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School, Tokyo, Japan. Electronic address: h-saeki@nms.ac.jp. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japanese Society of Allergology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus. To achieve this, topical anti-inflammatory drugs such as topical corticosteroids, tacrolimus ointment, delgocitinib ointment, and difamilast ointment have been used. However, the following treatments should be considered in addition to topical therapy for patients with refractory moderate-to-severe AD: oral cyclosporine, subcutaneous injections of biologics (dupilumab, nemolizumab, tralokinumab), oral Janus kinase inhibitors (baricitinib, upadacitinib, abrocitinib), and phototherapy. In the revised guidelines, descriptions of five new drugs, namely, difamilast, nemolizumab, tralokinumab, upadacitinib, and abrocitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansDisease ManagementJanus Kinase InhibitorsJapanReview Literature as Topic

Stichwörter der Autor:innen

Atopic dermatitisClinical practice guidelinesDecision-makingEvidence-based medicineTreatment

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School, Tokyo, Japan. Electronic address: h-saeki@nms.ac.jp.
  • Department of Occupational and Environmental Health, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Japan.
  • Kitakanto Allergy Research Institute, Kibounoie Hospital, Gunma, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Department of Pediatrics, The Jikei University Daisan Hospital, Tokyo, Japan.
  • North Campus of Kyoto Prefectural University of Medicine and Department for Medical Innovation and Translational Medical Science, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.

Förderung

  • Japanese Society of Allergology

Zitieren

APA

Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., Nagao, M., Narita, M., Hide, M., Fujisawa, T., Futamura, M., Masuda, K., Matsubara, T., Murota, H., Yamamoto-Hanada, K., …, & Japanese Dermatology Association (2025). Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024. Allergology International, 74(2), 210-221. https://doi.org/10.1016/j.alit.2025.01.003

Vancouver

Saeki H, Ohya Y, Arakawa H, Ichiyama S, Katsunuma T, Katoh N, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024. Allergology International. 2025;74(2):210-221. doi:10.1016/j.alit.2025.01.003

BibTeX
@article{Saeki2025,
  author = {Saeki, Hidehisa and Ohya, Yukihiro and Arakawa, Hirokazu and Ichiyama, Susumu and Katsunuma, Toshio and Katoh, Norito and Tanaka, Akio and Tanizaki, Hideaki and Tsunemi, Yuichiro and Nakahara, Takeshi and Nagao, Mizuho and Narita, Masami and Hide, Michihiro and Fujisawa, Takao and Futamura, Masaki and Masuda, Koji and Matsubara, Tomoyo and Murota, Hiroyuki and Yamamoto-Hanada, Kiwako and Furuta, Junichi and Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024, Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024 and Japanese Society of Allergology, Japanese Society of Allergology and Japanese Dermatology Association, Japanese Dermatology Association},
  title = {Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024},
  journal = {Allergology International},
  year = {2025},
  volume = {74},
  number = {2},
  pages = {210--221},
  doi = {10.1016/j.alit.2025.01.003}
}
Kostenlos starten →